Morgan Stanley maintains Royalty Pharma at Overweight
Morgan Stanley maintained its Overweight rating on Royalty Pharma, per Benzinga’s ratings actions recap.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Morgan Stanley maintains Overweight on Royalty Pharma; target raised
Morgan Stanley kept Royalty Pharma at Overweight and raised its price target to $67.00 from $65.00.